Pharmacovigilance in resource-limited countries

被引：104

作者：

Olsson, Sten ^{[1
]}

Pal, Shanthi N. ^{[2
]}

Dodoo, Alex ^{[3
]}

机构：

[1] WHO, Collaborating Ctr Int Drug Monitoring, S-75140 Uppsala, Sweden

[2] WHO, Safety & Vigilance, CH-1211 Geneva 27, Switzerland

[3] Univ Ghana, Sch Med & Dent, WHO, Collaborating Ctr Advocacy & Training Pharmacovig, Accra, Ghana

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2015年 / 8卷 / 04期

关键词：

adverse drug reactions; consumer involvement; drug regulation; harm; low and middle income countries; medicines; patient safety; Pharmacovigilance; public health programs; SAFETY; EVENTS;

D O I：

10.1586/17512433.2015.1053391

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In the past 20 years, many low- and middle-income countries have created national pharmacovigilance (PV) systems and joined the WHO's global PV network. However, very few of them have fully functional systems. Scientific evidence on the local burden of medicine-related harm and their preventability is missing. Legislation and regulatory framework as well as financial support to build sustainable PV systems are needed. Public health programs need to integrate PV to monitor new vaccines and medicines introduced through these programs. Signal analysis should focus on high-burden preventable adverse drug problems. Increased involvement of healthcare professionals from public and private sectors, pharmaceutical companies, academic institutions and the public at large is necessary to assure a safe environment for drug therapy. WHO has a major role in supporting and coordinating these developments.

引用

页码：449 / 460

页数：12

共 49 条

[1]

[Anonymous], 2014, Prescrire Int, V23, P302

[2]

[Anonymous], 1972, WHO TECHN REP, V498

[3]

[Anonymous], 2015, WHO | Pharmacovigilance

[4]

[Anonymous], 2010, ASSESSMENT OF MEDICI

[5]

[Anonymous], WHO GUIDELINES ON SA

[6]

[Anonymous], 2014, COMPARATIVE ANALYSIS

[7]

[Anonymous], 2000, SAFETY MONITORING OF

[8]

[Anonymous], 2012, PPB PHARMACOVIGILANC

[9]

[Anonymous], 2014, ER NAT PHARM POL STA

[10] Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys [J].

Avery, A. J. ;

Anderson, C. ;

Bond, C. M. ;

Fortnum, H. ;

Gifford, A. ;

Hannaford, P. C. ;

Hazell, L. ;

Krska, J. ;

Lee, A. J. ;

McLernon, D. J. ;

Murphy, E. ;

Shakir, S. ;

Watson, M. C. .

HEALTH TECHNOLOGY ASSESSMENT, 2011, 15 (20) :1-+

← 1 2 3 4 5 →